AbbVie Inc. is a global biopharmaceutical company whose portfolio spans immunology, oncology, neuroscience, and aesthetics. Because the broad average of all current analyst targets implies only a mid-single-digit premium to the share price, the $325 figure here is calculated as the mean of the verified targets that remain above the latest market price, in line with standard practice for a meaningful upside question.
Eight recent above-price targets were reviewed, including Morgan Stanley at $346 (Overweight, early November), Wells Fargo and BMO Capital each at $340, Cantor Fitzgerald at $325, Guggenheim at $322, Argus at $320, Freedom Capital Markets at $315, and Piper Sandler at $303. Their average rounds to $325. For context, the overall mean of all valid targets is roughly $306 to $310, and the full range spans from about $237 to $350, indicating that while most analysts are constructive, a meaningful minority remain cautious.
Recent actions skew bullish. Wolfe Research and Erste Group both upgraded the stock to Buy-equivalent ratings, while Morgan Stanley, Wells Fargo, Leerink Partners, and others lifted targets after third-quarter results. Analysts consistently cite Skyrizi and Rinvoq momentum, the neuroscience franchise, and a maturing pipeline as the core reasons behind higher targets.
ABBV last traded near $291, within sight of its 52-week high around $303. Reaching $325 would require a gain of about 11.6%—a modest move by equity-market standards, but still a meaningful step after the stock's already-strong rally of roughly 27% year to date.
The path would most plausibly run through continued execution in immunology and neuroscience. Third-quarter revenue grew about 10% year over year to roughly $17.4 billion, and management's initial 2027 commentary was described by Morgan Stanley as encouraging. A forward P/E (price-to-earnings ratio) near 18.5x also suggests the market is not yet pricing in aggressive multiple expansion, even though the trailing P/E is elevated following the recent earnings recovery.
Skyrizi and Rinvoq continue to deliver double-digit growth and are offsetting the long-anticipated decline of Humira as its exclusivity erodes. Neuroscience assets such as Vraylar, Ubrelvy, and Qulipta add diversification, while strategic deals—including the roughly $10 billion Apogee acquisition and smaller immunology and migraine collaborations—extend the pipeline. A forward valuation near the low end of large-cap pharma peers and a dividend yield around 2.5% provide additional ballast for the thesis.
The principal obstacles are competitive and valuation-related. Humira's erosion will continue to weigh on legacy revenue, and competitors are advancing in immunology and oncology, including pressure on Imbruvica. The trailing P/E above 50x reflects a rich recovery multiple that leaves little room for disappointment. Pipeline setbacks—such as underwhelming Phase 3 data for the hidradenitis suppurativa candidate lutikizumab—and U.S. drug-pricing negotiations under the Inflation Reduction Act also represent concrete downside risks that analysts themselves flag.
The stock's 52-week high near $303 marks the nearest resistance zone, and a decisive move through that level would be a precondition for sustained progress toward $325. The $300 round-number level carries psychological weight after the recent run. On the downside, the $280 area and the mid-$260s represent prior consolidation zones that could act as support. The long-term trend remains higher, but the proximity to all-time highs raises the bar for near-term follow-through.
Most analyst price targets reflect a roughly 12-month research horizon, though individual firms use different valuation frameworks and timelines. Investors should watch fourth-quarter and full-year earnings, updated 2027 guidance, Skyrizi and Rinvoq prescription trends, FDA decisions on pipeline programs, and any further M&A activity. Shifts in analyst estimates and target revisions will be among the clearest signals of whether the $325 level remains within reach.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single indicator, the system synthesizes multiple data streams to flag shifting trends as they develop. Traders and investors can use these signals to discover new opportunities, monitor existing positions, and spot changing market dynamics more efficiently than manual screening alone. For anyone tracking a large-cap name like ABBV, combining these AI signals with fundamental research can add a useful technical layer to the decision-making process.
Can ABBV reach $325? The question is reasonable: that level sits about 11.6% above the latest price and represents the average of the analyst targets that remain above the current quote. Support comes from accelerating immunology and neuroscience growth, a maturing pipeline, and a still-reasonable forward valuation. The counterweights are Humira erosion, intensifying competition, an elevated trailing multiple, and genuine analyst disagreement reflected in a target range spanning roughly $237 to $350. Whether the stock ultimately reaches $325 will depend on execution and on how the market weighs pipeline optionality against competitive and valuation risk—no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.94% | ||
| NVS - ABBV | 52% Loosely correlated | -0.50% | ||
| BMY - ABBV | 51% Loosely correlated | +0.79% | ||
| JNJ - ABBV | 51% Loosely correlated | +1.25% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.15% | ||
| GILD - ABBV | 47% Loosely correlated | -0.06% | ||
More | ||||